{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:22Z","timestamp":1792931962199,"version":"4.5.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with acute myeloid leukemia (AML) often undergo allogeneic hematopoietic cell transplantation (HCT) as it represents a highly effective treatment to prevent relapse of their disease. While HCT is an important part of curative therapy for many AML patients, post-HCT relapse still occurs, and so post-HCT maintenance therapy is offered to some patients\u2014often without any reliable evidence supporting its use. More and more molecularly targeted drugs are emerging in the field, and while there is randomized data supporting the use of FLT3 inhibitors in this setting, no other drug class has been convincingly shown to benefit these patients (yet). In acknowledgment of the fact that clinicians will continue to offer post-HCT maintenance in the hope of improving outcomes, this review focuses on the data (or lack thereof) directly supporting this practice, as well as some of the pitfalls that can be encountered with these drugs when used as maintenance.<\/jats:p>","DOI":"10.1182\/hematology.2025000746","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:09:41Z","timestamp":1764943781000},"page":"531-536","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Post-HCT maintenance therapy for AML: who, when, why, how long?"],"prefix":"10.1182","volume":"2025","author":[{"given":"Mark","family":"Levis","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"12","key":"2025120616344344400_hem2025000746C1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025120616344344400_hem2025000746C2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2025120616344344400_hem2025000746C3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2025120616344344400_hem2025000746C4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbmt.2019.10.017","article-title":"Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research study","volume":"26","author":"DeFilipp","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2025120616344344400_hem2025000746C5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2025120616344344400_hem2025000746C6","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2025120616344344400_hem2025000746C7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"2025120616344344400_hem2025000746C8","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2025120616344344400_hem2025000746C9","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025120616344344400_hem2025000746C10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41409-024-02449-2","article-title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"2025120616344344400_hem2025000746C11","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD- mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"5","key":"2025120616344344400_hem2025000746C12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"2025120616344344400_hem2025000746C13","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"10388","key":"2025120616344344400_hem2025000746C14","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"2025120616344344400_hem2025000746C15","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025120616344344400_hem2025000746C16","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2006-07-012252","article-title":"Acute myeloid leukemia carrying cytoplasmic\/mutated nucleophosmin (NPMc+ AML): biologic and clinical features","volume":"109","author":"Falini","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2025120616344344400_hem2025000746C17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.2019002180","article-title":"FLT3 inhibitors added to induction therapy induce deeper remissions","volume":"135","author":"Levis","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2025120616344344400_hem2025000746C18","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.20090746","article-title":"Feedback control of regulatory T cell homeostasis by dendritic cells in vivo","volume":"206","author":"Darrasse-J\u00e8ze","year":"2009","journal-title":"J Exp Med"},{"issue":"2","key":"2025120616344344400_hem2025000746C19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/eji.201242603","article-title":"Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects","volume":"43","author":"Klein","year":"2013","journal-title":"Eur J Immunol"},{"issue":"26","key":"2025120616344344400_hem2025000746C20","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025120616344344400_hem2025000746C21","doi-asserted-by":"crossref","first-page":"1095870","DOI":"10.3389\/fonc.2023.1095870","article-title":"Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption","volume":"13","author":"Morin","year":"2023","journal-title":"Front Oncol"},{"issue":"20","key":"2025120616344344400_hem2025000746C22","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML","volume":"120","author":"Sexauer","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2025120616344344400_hem2025000746C23","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025120616344344400_hem2025000746C24","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","article-title":"Inhibition of c-Kit by tyrosine kinase inhibitors","volume":"100","author":"Galanis","year":"2015","journal-title":"Haematologica"},{"issue":"29","key":"2025120616344344400_hem2025000746C25","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","article-title":"Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status","volume":"31","author":"Cortes","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025120616344344400_hem2025000746C26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025120616344344400_hem2025000746C27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025120616344344400_hem2025000746C28","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"2025120616344344400_hem2025000746C29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.V126.23.323.323","article-title":"Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1\/2 trial","volume":"126","author":"Stein","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2025120616344344400_hem2025000746C30","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2025120616344344400_hem2025000746C31","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2025120616344344400_hem2025000746C32","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","article-title":"Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia","volume":"29","author":"Fathi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025120616344344400_hem2025000746C33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41409-024-02447-4","article-title":"Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025120616344344400_hem2025000746C34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025120616344344400_hem2025000746C35","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"issue":"24","key":"2025120616344344400_hem2025000746C36","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood.2024026605","article-title":"Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia","volume":"144","author":"Loo","year":"2024","journal-title":"Blood"},{"issue":"21","key":"2025120616344344400_hem2025000746C37","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"2025120616344344400_hem2025000746C38","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"2025120616344344400_hem2025000746C39","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"36","key":"2025120616344344400_hem2025000746C40","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025120616344344400_hem2025000746C41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2025120616344344400_hem2025000746C42","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","article-title":"Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML","volume":"8","author":"Garcia","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2025120616344344400_hem2025000746C43","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2025120616344344400_hem2025000746C44","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 Maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025120616344344400_hem2025000746C45","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.287177","article-title":"Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome","author":"Smallbone","year":"2025","journal-title":"Haematologica"},{"issue":"2","key":"2025120616344344400_hem2025000746C46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ajh.24959","article-title":"Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant","volume":"93","author":"Sandmaier","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"2025120616344344400_hem2025000746C47","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"58","author":"Kent","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"7954","key":"2025120616344344400_hem2025000746C48","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/531\/2470463\/531levis.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/531\/2470463\/531levis.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:34:54Z","timestamp":1765056894000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/531\/556877\/Post-HCT-maintenance-therapy-for-AML-who-when-why"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000746","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}